41 results on '"R. Alfonso-Cristancho"'
Search Results
2. Mepolizumab Reduces Clinically Significant Exacerbations in Patients With Severe Asthma Prior to and During the COVID-19 Pandemic: Results From the Real-world REALITI-A Study
3. Characteristics of Patients With Moderate-to-Severe Asthma and High Healthcare Costs in the United States
4. Content Validity of the Asthma Daytime Symptom Diary and Asthma Nighttime Symptom Diary in Patients With Moderate-to-Severe Asthma
5. Clinical Manifestations and Health Care Resource Utilization of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in China: A Multi-center Retrospective Cohort Study in China (Interim Analysis)
6. Demographic Characteristics of Patients Who Utilize Biologics for Severe Asthma: A Real-World European Perspective
7. Demographics and Characteristics of Patients Who Initiate Biologics for Severe Asthma in Japan
8. The Validity of the Asthma Daytime Symptoms Diary (ADSD) and the Asthma Nighttime Symptoms Diary (ANSD) As Measures of Symptoms in Patients With Moderate-to-Severe Asthma
9. Blood Eosinophil and IgE Levels at Initiation of Biologics for the Treatment of Severe Asthma, a Perspective From US, EU-4, and UK
10. L’impact de la comorbidité des polypes nasaux sur l’efficacité en vraie vie du mépolizumab chez les patients souffrant d’asthme sévère : résultats de l’étude REALITI-A
11. Mepolizumab effectiveness in severe asthma supported by federated analysis of European SHARP data
12. Disease burden and treatment patterns among patients with asthma on GINA 4/5 therapies in China
13. Disease burden and treatment patterns among patients with asthma in China
14. Retrospective study characterising clinical manifestations and treatment patterns of hypereosinophilic syndrome in Europe
15. Characterisation and burden of eosinophilic granulomatosis with polyangiitis: a European retrospective study
16. International, prospective study of mepolizumab in severe asthma: REALITI-A at 2yrs
17. Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP
18. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma
19. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study
20. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study
21. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study
22. Différences entre les pays en ce qui concerne le fardeau des patients atteints de syndrome hyperéosinophilique en Europe
23. HSD58 Country Differences in the Clinical Manifestations and Treatment Patterns of Patients With Eosinophilic Granulomatosis With Polyangiitis (EGPA): A European Perspective
24. P1035: COUNTRY DIFFERENCES IN THE BURDEN OF PATIENTS WITH HYPEREOSINOPHILIC SYNDROME IN EUROPE
25. P1034: HEALTHCARE UTILIZATION OF PATIENTS WITH HYPEREOSINOPHILIC SYNDROME IN EUROPE
26. Influence des IgE totales à l’inclusion et des antécédents d’utilisation d’omalizumab sur l’impact du mépolizumab sur la réduction du taux d’exacerbations sévères de l’asthme : résultats de l’étude REALITI-A en vie réelle
27. EE607 Healthcare Utilisation of Patients With Eosinophilic Granulomatosis With Polyangiitis (EGPA): A European Perspective
28. THE SUSTAINED OCS-SPARING EFFECT OF MEPOLIZUMAB: RESULTS FROM THE REAL-WORLD REALITI-A STUDY AT 2 YEARS
29. Revue systématique des études en vie réelle d’efficacité et de tolérance de mépolizumab dans le traitement de l’asthme sévère éosinophilique
30. Real-world Effectiveness of Mepolizumab in Reducing Asthma Exacerbations in Japan
31. International Differences in the Use of Mepolizumab to Treat Severe Asthma - Impact of Reimbursement Policies
32. How Real-World Mepolizumab Users in the REALITI-A Study Relate to the Recruitment Criteria Applied in the Randomized, Placebo-Controlled Trials of Subcutaneous Mepolizumab in Severe Eosinophilic Asthma
33. PCR137 Work Productivity and Activity Impairment in Patients with Severe Asthma Treated with Mepolizumab in a Real-World Setting
34. EE298 Clinical Manifestations and Health Care Resource Utilization of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in China: A Cross-Sectional Multi-Center Physician Survey Study
35. L’impact de la fraction exhalée de l’oxyde nitrique (NO) et du taux d’éosinophiles sanguin à l’inclusion sur les résultats cliniques dans REALITI-A
36. Le bénéfice clinique du traitement par mépolizumab est indépendant de l’utilisation initiale de corticostéroïdes oraux : résultats de l’étude de vraie vie REALITI-A
37. Étude prospective internationale en vie réelle du mépolizumab chez les patients souffrant d’asthme sévère à un an: REALITI-A
38. SAT0223 Indirect comparative clinical effectiveness of intravenous and subcutaneous formulations of belimumab for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus with high disease activity
39. Methodological Concerns of a Recent Network Meta-analysis Assessing Biologics for Eosinophilic Asthma
40. Can We Make Better Decisions If We Remove Quality of Life from the Value Equation?
41. Effectiveness of a Medical vs Revascularization Intervention for Intermittent Leg Claudication Based on Patient-Reported Outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.